Petracci, Elisabetta

Impact of TP53 Mutations on Outcome in EGFR -Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors

Canale, M., Petracci, E., Delmonte, A., Chiadini, E., Dazzi, C., Papi, M., Capelli, L., Casanova, C., De Luigi, N., Mariotti, M., et al. (2017) · Clinical Cancer Research

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 288

Resource utilization and cost saving analysis of subcutaneous versus intravenous trastuzumab in early breast cancer patients

Farolfi, A., Silimbani, P., Gallegati, D., Petracci, E., Schirone, A., Altini, M., & Masini, C. (2017) · Oncotarget

Health Systems, Economic Evaluations, Quality of LifeEconomic and Financial Impacts of Cancer

Cited by 19